PT2200436E - Pirimidinilaminas substituídas como inibidoras da proteína quinase - Google Patents
Pirimidinilaminas substituídas como inibidoras da proteína quinase Download PDFInfo
- Publication number
- PT2200436E PT2200436E PT88299433T PT08829943T PT2200436E PT 2200436 E PT2200436 E PT 2200436E PT 88299433 T PT88299433 T PT 88299433T PT 08829943 T PT08829943 T PT 08829943T PT 2200436 E PT2200436 E PT 2200436E
- Authority
- PT
- Portugal
- Prior art keywords
- amines
- protein kinase
- kinase inhibitors
- substituted pyrimidinyl
- pyrimidinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96984907P | 2007-09-04 | 2007-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2200436E true PT2200436E (pt) | 2015-04-29 |
Family
ID=40429327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT88299433T PT2200436E (pt) | 2007-09-04 | 2008-09-03 | Pirimidinilaminas substituídas como inibidoras da proteína quinase |
Country Status (7)
Country | Link |
---|---|
US (3) | US8530480B2 (pt) |
EP (1) | EP2200436B1 (pt) |
JP (2) | JP5611826B2 (pt) |
CA (1) | CA2698511C (pt) |
ES (1) | ES2535166T3 (pt) |
PT (1) | PT2200436E (pt) |
WO (1) | WO2009032861A1 (pt) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010513384A (ja) | 2006-12-22 | 2010-04-30 | エフ.ホフマン−ラ ロシュ アーゲー | スピロ−ピペリジン誘導体 |
AU2016200866B2 (en) * | 2007-03-12 | 2017-06-22 | Glaxosmithkline Llc | Phenyl amino pyrimidine compounds and uses thereof |
AU2013201306B2 (en) * | 2007-03-12 | 2015-11-12 | Glaxosmithkline Llc | Phenyl Amino Pyrimidine Compounds and Uses Thereof |
PL2152701T3 (pl) | 2007-03-12 | 2016-10-31 | Związki fenyloaminopirymidyny i ich zastosowania | |
US8507511B2 (en) * | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
US8530480B2 (en) | 2007-09-04 | 2013-09-10 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
BRPI0906799A2 (pt) | 2008-01-11 | 2015-07-14 | Hoffmann La Roche | Moduladores para amiloide beta |
CA2713716A1 (en) | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
KR101324414B1 (ko) | 2008-10-09 | 2013-11-01 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타의 조절자 |
WO2010052199A1 (en) | 2008-11-10 | 2010-05-14 | F. Hoffmann-La Roche Ag | Heterocyclic gamma secretase modulators |
CN102791697A (zh) * | 2009-10-12 | 2012-11-21 | 瑞科西有限公司 | 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物 |
EP2512246B1 (en) | 2009-12-17 | 2015-09-30 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
SG181803A1 (en) | 2009-12-17 | 2012-07-30 | Merck Sharp & Dohme | Aminopyrimidines as syk inhibitors |
US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
CN104086528A (zh) | 2010-07-15 | 2014-10-08 | 拜耳知识产权有限责任公司 | 作为杀虫剂的新杂环化合物 |
GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
EP2598660B1 (en) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
WO2012052412A1 (de) | 2010-10-22 | 2012-04-26 | Bayer Cropscience Ag | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
EP2681215B1 (en) | 2011-02-28 | 2015-04-22 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
JP6147727B2 (ja) | 2011-04-01 | 2017-06-14 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼbtk阻害剤としての置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体 |
JP2014510794A (ja) * | 2011-04-12 | 2014-05-01 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド | IKK関連キナーゼεおよびTANK結合キナーゼ1の阻害剤の組成物および治療的使用 |
ES2613103T3 (es) | 2011-04-19 | 2017-05-22 | Bayer Intellectual Property Gmbh | 4-Aril-n-fenil-1,3,5-triacin-2-aminas sustituidas |
EP2707357B1 (en) | 2011-05-10 | 2017-01-18 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
MX2013013090A (es) | 2011-05-10 | 2013-12-16 | Merck Sharp & Dohme | Aminopirimidinas como inhibidores de tirosina cinaza del bazo. |
EP2706852B1 (en) | 2011-05-10 | 2018-08-22 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
KR20140045542A (ko) * | 2011-07-12 | 2014-04-16 | 다우 아그로사이언시즈 엘엘씨 | 살충 조성물 및 그에 관한 방법 |
MX340756B (es) | 2011-08-04 | 2016-07-25 | Array Biopharma Inc | Compuestos de quinazolina como inhibidores de serina/treonina quinasa. |
DE102011112978A1 (de) | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
ES2588102T3 (es) | 2011-09-16 | 2016-10-28 | Bayer Intellectual Property Gmbh | Derivados de 5-fluoro-pirimidina disustituidos que contienen un grupo sulfoximina |
EP2755956B1 (en) | 2011-09-16 | 2016-05-18 | Bayer Intellectual Property GmbH | 2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors |
LT3321262T (lt) | 2012-03-01 | 2021-06-10 | Array Biopharma, Inc. | Serino/treonino kinazės inhibitoriai |
IL289834B1 (en) | 2012-06-13 | 2024-03-01 | Incyte Holdings Corp | Conversion of tricyclic compounds as FGFR inhibitors |
US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
RU2644947C2 (ru) | 2012-08-27 | 2018-02-15 | Аррэй Байофарма Инк. | Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний |
JP6313772B2 (ja) * | 2012-10-04 | 2018-04-18 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼbtk阻害剤である置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体 |
JP6401169B2 (ja) | 2012-10-04 | 2018-10-03 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼbtk阻害剤としての置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体 |
CA2888381A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
CN104854091B (zh) | 2012-10-18 | 2018-04-03 | 拜耳药业股份公司 | 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物 |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
EP2934572A4 (en) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS |
GB201303109D0 (en) * | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
EP3007556B1 (en) | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Cell stabilization |
EP3942931A1 (en) | 2014-06-10 | 2022-01-26 | Biomatrica, INC. | Stabilization of thrombocytes at ambient temperatures |
TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
ES2720525T3 (es) | 2014-10-16 | 2019-07-22 | Bayer Pharma AG | Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfona |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
WO2016150902A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers |
WO2016150903A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas |
JP2018509439A (ja) | 2015-03-24 | 2018-04-05 | バイエル ファーマ アクチエンゲゼルシャフト | 多発性骨髄腫を治療するための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用 |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
US20180194769A1 (en) | 2015-07-06 | 2018-07-12 | Rodin Therapeutics, Inc. | Hetero-halo inhibitors of histone deacetylase |
JP6847099B2 (ja) | 2015-09-29 | 2021-03-24 | バイエル ファーマ アクチエンゲゼルシャフト | 新規な大環状スルホンジイミン化合物 |
WO2017060167A1 (en) | 2015-10-08 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Novel modified macrocyclic compounds |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
DK3362445T3 (da) | 2015-10-12 | 2023-02-27 | Chong Kun Dang Pharmaceutical Corp | Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed |
EP3387411B1 (en) | 2015-12-08 | 2023-05-10 | Biomatrica, INC. | Reduction of erythrocyte sedimentation rate |
CN110818690B (zh) | 2016-07-26 | 2021-08-10 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
US20190231751A1 (en) * | 2016-09-12 | 2019-08-01 | Imago Pharmaceuticals, Inc. | Treatment of fibrotic disorders with jun n-terminal kinase inhibitors |
US10793567B2 (en) | 2017-01-11 | 2020-10-06 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
WO2018152223A1 (en) * | 2017-02-15 | 2018-08-23 | University Of Massachusetts | Methods of treating angiogenesis-related disorders using jnk3 inhibitors |
GB201702947D0 (en) | 2017-02-23 | 2017-04-12 | Domainex Ltd | Novel compounds |
PL3601253T3 (pl) | 2017-03-28 | 2022-01-17 | Bayer Aktiengesellschaft | Nowe hamujące ptefb związki makrocykliczne |
EP3601236A1 (en) | 2017-03-28 | 2020-02-05 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3664802B1 (en) | 2017-08-07 | 2022-02-23 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
US20230019491A1 (en) * | 2017-10-17 | 2023-01-19 | Srinivasa R. Karra | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF |
SG11202003441VA (en) * | 2017-10-17 | 2020-05-28 | Merck Patent Gmbh | PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF |
CA3086765A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
IL276437B2 (en) | 2018-02-13 | 2024-03-01 | Bayer Ag | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for the treatment of diffuse large B-cell lymphoma |
MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
EP3788047A2 (en) | 2018-05-04 | 2021-03-10 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
MX2021003516A (es) * | 2018-09-25 | 2021-05-27 | Cardurion Pharmaceuticals Llc | Compuesto de aminopirimidina. |
WO2020068846A1 (en) * | 2018-09-25 | 2020-04-02 | Heterocyclic Compound | Heterocyclic compound |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
BR112022007163A2 (pt) | 2019-10-14 | 2022-08-23 | Incyte Corp | Heterociclos bicíclicos como inibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4876252A (en) | 1986-01-13 | 1989-10-24 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
EP0233461B2 (en) * | 1986-01-13 | 2002-05-29 | American Cyanamid Company | 4,5,6-Substituted-2-pyrimidinamines |
US4788195A (en) * | 1986-01-13 | 1988-11-29 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
TW225528B (pt) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ATE325113T1 (de) * | 1993-10-01 | 2006-06-15 | Novartis Pharma Gmbh | Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
ES2292753T4 (es) * | 2001-03-29 | 2009-02-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas. |
DE60212836T2 (de) * | 2001-05-16 | 2007-01-25 | Gpc Biotech Ag | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
DE60330895D1 (de) | 2002-11-01 | 2010-02-25 | Vertex Pharma | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen |
JP4688498B2 (ja) * | 2002-11-04 | 2011-05-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakインヒビターとしてのヘテロアリール−ピリミジン誘導体 |
JP2006508107A (ja) * | 2002-11-05 | 2006-03-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakおよび他のプロテインキナーゼのインヒビターとして有用な化合物 |
GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
CA2533474A1 (en) * | 2003-07-30 | 2005-02-10 | Shudong Wang | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
JP2008510766A (ja) * | 2004-08-27 | 2008-04-10 | ゲーペーツェー ビオテック アーゲー | ピリミジン誘導体 |
TW200626559A (en) * | 2004-10-13 | 2006-08-01 | Wyeth Corp | Anilino-pyrimidine analogs |
WO2007081690A2 (en) | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EP1979329A2 (en) * | 2006-01-30 | 2008-10-15 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use |
US20100145851A1 (en) | 2006-12-18 | 2010-06-10 | Fundamo (Proprietary) Limited | Transaction system with enhanced instruction recognition |
EP2094682A2 (en) * | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
AT504205B1 (de) * | 2007-01-02 | 2008-04-15 | Hoermann Richard Dr | Einrichtung zur entkeimung eines fluids |
EP2118105A1 (en) * | 2007-01-23 | 2009-11-18 | Palau Pharma, S.A. | Purine derivatives |
PL2152701T3 (pl) | 2007-03-12 | 2016-10-31 | Związki fenyloaminopirymidyny i ich zastosowania | |
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
US8530480B2 (en) | 2007-09-04 | 2013-09-10 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
WO2009103032A1 (en) * | 2008-02-15 | 2009-08-20 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
CA2713716A1 (en) * | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
-
2008
- 2008-09-03 US US12/676,411 patent/US8530480B2/en not_active Expired - Fee Related
- 2008-09-03 CA CA2698511A patent/CA2698511C/en not_active Expired - Fee Related
- 2008-09-03 EP EP08829943.3A patent/EP2200436B1/en not_active Not-in-force
- 2008-09-03 WO PCT/US2008/075151 patent/WO2009032861A1/en active Application Filing
- 2008-09-03 PT PT88299433T patent/PT2200436E/pt unknown
- 2008-09-03 ES ES08829943.3T patent/ES2535166T3/es active Active
- 2008-09-03 JP JP2010524122A patent/JP5611826B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-13 US US13/766,075 patent/US9018205B2/en not_active Expired - Fee Related
-
2014
- 2014-09-02 JP JP2014177846A patent/JP5937648B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-27 US US14/696,935 patent/US20150232429A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5611826B2 (ja) | 2014-10-22 |
US20130231336A1 (en) | 2013-09-05 |
US20150232429A1 (en) | 2015-08-20 |
EP2200436A4 (en) | 2011-12-28 |
US8530480B2 (en) | 2013-09-10 |
EP2200436B1 (en) | 2015-01-21 |
CA2698511A1 (en) | 2009-03-12 |
JP2010538076A (ja) | 2010-12-09 |
JP2015007102A (ja) | 2015-01-15 |
ES2535166T3 (es) | 2015-05-06 |
US9018205B2 (en) | 2015-04-28 |
US20100298312A1 (en) | 2010-11-25 |
CA2698511C (en) | 2016-10-11 |
WO2009032861A1 (en) | 2009-03-12 |
EP2200436A1 (en) | 2010-06-30 |
JP5937648B2 (ja) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1900014I1 (hu) | Proteinkináz inhibitorok | |
EP2200436A4 (en) | SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER | |
IL206416A0 (en) | Benzofuropyrimidinones as protein kinase inhibitors | |
PL2193133T3 (pl) | Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej | |
IL210073A0 (en) | Protein kinase inhibitors | |
SI2201012T1 (sl) | Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B | |
HK1146042A1 (en) | Pyrimidine derivatives as protein kinase inhibitors | |
IL210069A0 (en) | Protein kinase inhibitors | |
HRP20130698T1 (en) | Novel phenylpyrazinones as kinase inhibitors | |
HRP20130787T1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
IL198487A0 (en) | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | |
IL198398A0 (en) | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | |
EP2336123A4 (en) | HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE | |
HK1151291A1 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
HK1142592A1 (en) | Alkynylpyrimidines as tie2 kinase inhibitors | |
EP2136829A4 (en) | INHIBITORS OF BINDING TO A PROTEIN KINASE | |
EP2231152A4 (en) | THIENOPYRANONES AS KINASE INHIBITORS | |
IL194491A0 (en) | Thiazolyldihydroindazole derivatives as protein kinase inhibitors | |
ZA200810573B (en) | Substituted 3-cyanopyridines as protein kinase inhibitors | |
EP2254566A4 (en) | INHIBITORS OF BINDING TO PROTEIN KINASE | |
GB0715470D0 (en) | IKK- serine-threonine protein kinase inhibitors | |
GB0807642D0 (en) | IKK- serine-threonine protein kinase inhibitors | |
GB0621719D0 (en) | Ikk- serine-threonine protein kinase inhibitors | |
GB0807908D0 (en) | ikk-beta serine-theronine protein kinase inhibitors |